Up to 200 Thousand Euros Support Per Project for Personalized Cell and Gene Therapies

The 2027 call titled "Cell and Gene Therapies for a Personalized Medicine Approach (CGT4PM2027)" by the European Partnership for Personalised Medicine (EP PerMed) has been opened for applications. The total contribution that partners in Turkey can request from TÜBİTAK per project cannot exceed 200 thousand euros.

According to the information provided by TÜBİTAK, research projects aimed at developing innovative cell and gene therapies for human health will be supported within the scope of the call. While the projects are planned to last a maximum of 36 months, researchers will be able to propose projects in all disease areas. Applications are required to use at least one of the approaches for somatic cells, genes, combined cell and gene therapies, or novel biological products.

Higher education institutions, research and training hospitals, research infrastructures, public institutions, and capital companies holding a trade registry certificate from Turkey will be able to apply. Consortia must include at least 3 independent partners from at least 3 different EU member states or countries associated with the Horizon Europe Program, who will receive support from their respective funders. The upper limit to be requested from TÜBİTAK for partners in Turkey will be applied as 100 thousand euros for higher education and public institutions, and 200 thousand euros for private organizations.

International short project proposals must be submitted in English by January 20, 2027. The first-stage national applications to be made by partners in Turkey to TÜBİTAK will be completed by January 27, 2027. The deadline for international project proposals for the second stage has been set as May 25, 2027, and projects are projected to begin in December 2027.